Použitá literatura a internetové zdroje:
ANDERSEN, Kristian G., et al. The proximal origin of SARS-CoV-2. Nature Medicine, 2020, 26.4: 450-452. Dostupné online
DEVAUX, Christian A., et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. International journal of antimicrobial agents, 2020, 105938. Dostupné online
CAO, Bin, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine, 2020. (Epub ahead of print on March 18, 2020). Dostupné online
HOFFMANN, Markus, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181, 1-10. Dostupné online
LIU, Cynthia, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Central Science, 2020, 6: 315-331. Dostupné online
ZHANG, Linlin, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, 2020. (Epub ahead of print on March 20, 2020). Dostupné online
Centers for Disease Control and Prevention, SARS https://www.cdc.gov/sars/
Gilead Sciences, Inc. www.gilead.com
